Release Date: 2024-06-19

Apalutamide Therapy for Metastatic Prostate Cancer

Eyyup Sabri Pelit (Author), Mustafa Kaan Akalin (Author)

Release Date: 2024-06-19

In this section, apalutamide and androgen Deprivation Therapy (ADT) are recommended for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC). Apalutamide, as a second-generation androgen receptor inhibitor, extends progression-free survival and overall survival when used in combination with ADT. Clinical trials have demonstrated that the combination of apalutamide and ADT is more effective and better [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page97
    Last Page104
    DOIhttps://doi.org/10.69860/nobel.9786053359142.9
    Page Count8
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    In this section, apalutamide and androgen Deprivation Therapy (ADT) are recommended for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC). Apalutamide, as a second-generation androgen receptor inhibitor, extends progression-free survival and overall survival when used in combination with ADT. Clinical trials have demonstrated that the combination of apalutamide and ADT is more effective and better tolerated compared to ADT alone. As an innovative non-steroidal anti-androgen, apalutamide exhibits higher affinity to the androgen receptor and prevents androgen receptor translocation, thereby eliminating potential agonistic effects compared to traditional anti-androgens. Clinical data have shown positive outcomes in patients treated with apalutamide, such as decreased levels of prostate-specific antigen (PSA) and extended overall survival. Therefore, apalutamide is recommended for patients with mHSPC who are not suitable for docetaxel therapy.

    Eyyup Sabri Pelit (Author)
    MD, Associate Professor of Urology, Harran University
    https://orcid.org/0000-0001-8550-5072
    3After graduating from Marmara University Faculty of Medicine, Eyyup Sabri Pelit completed his urology specialization at Istanbul Medeniyet University Urology Clinic. He achieved the European Qualifications Board examination.After becoming a urology specialist, he became an associate professor at Harran University Urology Clinic and is still working as an associate professor in Harran Univercity School of Medicine. He has many national and international studies in the field of urology. He currently focuses on the urooncology and andrology field.He is an active member of both the Turkish Society of Urology and the European Assosiation Urology.

    Mustafa Kaan Akalin (Author)
    MD, Ozalp State Hospital
    https://orcid.org/0000-0003-1484-2906
    3Dr. Mustafa Kaan Akalin has been a dedicated professional in the field of urology for over six years. He completed his undergraduate education at the Adnan Menderes Faculty of Medicine and subsequently Later, he became a urologist specialist with a residency at Istanbul Medeniyet University. Dr. Akalin has a distinguished record of scholarly contributions, having authored over 10 research articles and presented numerous oral and poster presentations. His current research focuses on the urooncology and endourology.He is an active member of both the Turkish Society of Urology and the European Assosiation Urology.

    • Tilki D, Roderick CN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;0302-2838.

    • Agarwal N, McQuarrie K, Bjartell A, et al: Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): A randomised, placebo-controlled, phase 3 study. Lancet Oncol 2019;20:1518- 1530.

    • Chi KN, Chowdhury S, et al: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 2021;39(20):2294-2303.

    • Chi KN, Agarwal N, Bjartell A, et al: Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13-24.

    • Lowrance W, Dreicer R, et al: Updates to Advanced Prostate Cancer: AUA/SUOGuideline (2023). J Urol 2023;209:1082-1090.

    • Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis- free survival in prostate cancer. N Engl J Med 2018;378:1408-18.

    • Parker C, Castro E, Fizazi K, et al: Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1119-1134.

    • Merseburger, A.S., et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. Eur J Cancer 2023;193:113290.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!